18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Florian Moog - , Ulm University (Author)
  • Markus Bangerter - , Ulm University (Author)
  • Jörg Kotzerke - , Ulm University (Author)
  • Albrecht Guhlmann - , Ulm University (Author)
  • Norbert Frickhofen - , Ulm University (Author)
  • Sven N. Reske - , Ulm University (Author)

Abstract

Purpose: Bone marrow involvement in patients with malignant lymphoma is considered a sign of generalized disease with less favorable prognosis. Bone marrow biopsy (BMB), which represents the standard diagnostic procedure, however, is associated with a high rate of false-negative findings, which may lead to errors in management. The present study was undertaken to investigate the efficacy of positron emission tomography (PET) with 18-F- fluorodeoxyglucose (FDG-PET) as a new method to evaluate bone marrow involvement in Patients with malignant lymphoma. Methods: Seventy-eight consecutive, untreated patients with either non-Hodgkin's lymphoma (NHL; n = 39) or Hodgkin's disease (HD; n = 39) were prospectively evaluated. Static FDG-PET imaging was performed following application of 270 MBq (F-18)-FDG. Attenuation correction was performed in 63 of 78 patients. Visual evaluation was performed by two examiners unaware of the clinical data. Material for BMB (70 bilateral, 8 unilateral) was obtained from the posterior lilac crest. Discordant results of PET and biopsy were settled, when possible, on the basis of further biopsy or magnetic resonance imaging (MRI). Results: In addition to seven concordant positive and 57 concordant negative findings, biopsy revealed another four cases with bone marrow involvement not detectable by FDG-PET analysis (+5.1%). On the contrary, PET showed bone marrow areas of intensive FDG uptake that suggested bone marrow lymphoma in 10 patients with negative biopsies (+ 12.8%). In eight patients, FDG-PET findings were confirmed by either histologic verification (n = 4), MRI (n = 2), polymerase chain reaction (PCR) for rearranged immunoglobulin H sequences (n = 1), or clinical presentation (n = 1). Two cases remained unresolved. Conclusion: The results indicate that FDG-PET has a high potential to detect bone marrow involvement in malignant lymphoma. Besides confirming lesions found at BMB, FDG-PET provided additional information, which, in eight of 78 patients (10.3%), led to an upgrade of the tumor stage.

Details

Original languageEnglish
Pages (from-to)603-609
Number of pages7
JournalJournal of clinical oncology
Volume16
Issue number2
Publication statusPublished - Feb 1998
Peer-reviewedYes
Externally publishedYes

Keywords

Sustainable Development Goals

ASJC Scopus subject areas

Library keywords